{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:54:23Z","timestamp":1793066063745,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007930.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000}}],"reference-count":399,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007930.pub3","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T06:30:43Z","timestamp":1681799443000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Angiogenesis inhibitors for the treatment of epithelial ovarian cancer"],"prefix":"10.1002","volume":"2023","author":[{"given":"Kezia","family":"Gaitskell","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Unit, Nuffield Department of Population Health; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Rogozi\u0144ska","sequence":"additional","affiliation":[{"name":"The Evidence-Based Medicine Consultancy Ltd; Bath UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Platt","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynaecology; St Mary's Hospital, University Hospitals Bristol and Weston NHS Foundation Trust; Bristol UK"},{"name":"Department of Gynaecological Oncology; St. Michael's Hospital; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Chen","sequence":"additional","affiliation":[{"name":"Oxford Medical School; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abd El Aziz","sequence":"additional","affiliation":[{"name":"Internal Medicine Department; Mercyone North Iowa; Mason City Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Tattersall","sequence":"additional","affiliation":[{"name":"Kingston Hospital NHS Foundation Trust; Kingston upon Thames UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Morrison","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology; Musgrove Park Hospital, Somerset NHS Foundation Trust; Taunton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"key":"10.1002\/14651858.CD007930.pub3-BIB0001|cit1","unstructured":"Du Bois A Kristensen G Ray-Coquard I Reus A Pignata S Colombo N AGO-OVAR 12: A randomized placebo-controlled GCIG\/ENGOT-Intergroup phase III trial of standard frontline chemotherapy +\/-nintedanib for advanced ovarian cancer International Journal of Gynecological Cancer 2013 7 8"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007930.pub3-BIB0002|cit2","first-page":"74","article-title":"AGO-OVAR 12: a randomized placebo-controlled GCIG\/ENGOT-Intergroup phase III trial of standard frontline chemotherapy +\/- nintedanib for advanced ovarian cancer","volume":"37","author":"Harter","year":"2014","journal-title":"Oncology Research and Treatment"},{"issue":"15","key":"10.1002\/14651858.CD007930.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.1200\/jco.2014.32.15_suppl.5556","article-title":"Independent review of AGO-OVAR 12, a GCIG\/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC)","volume":"32","author":"Kristensen","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0004|cit4","unstructured":"LUME-Ovar 1: BIBF 1120 or placebo in combination with paclitaxel and carboplatin in first line treatment of ovarian cancer www.clinicaltrials.gov\/ct2\/show\/NCT01015118"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/ijc.32606","article-title":"Final results from GCIG\/ENGOT\/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer","volume":"146","author":"Ray-Coquard","year":"2020","journal-title":"International Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","article-title":"Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"17","author":"du Bois","year":"2016","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0007|cit7","unstructured":"Del Campo J M Kurzeder C Berton-Rigaud D Kim B G Friedlander M Zamagni C Progression-free survival by GCIG criteria: analysis of the secondary endpoint of the AGO-OVAR16 trial 18th International Meeting of the European Society of Gynaecological Oncology 2013"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0008|cit8","first-page":"LBA5503","article-title":"Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international Intergroup trial (AGO-OVAR16)","volume":"31","author":"Du Bois","year":"2013","journal-title":"Journal of Clinical Oncology, ASCO Annual Meeting Abstracts"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0009|cit9","unstructured":"Floquet A Vergote I Colombo N Fiane B Monk B J Reinthaller A Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 trial 18th International Meeting of the European Society of Gynaecological Oncology 2013"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ygyno.2014.11.074","article-title":"Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial","volume":"136","author":"Floquet","year":"2015","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0011|cit11","unstructured":"Friedlander M Knoll S Meier W Lesoin A Kim JW Poveda A Quality of life in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC) receiving either pazopanib monotherapy or placebo after first-line chemotherapy: AGO-OVAR16 results European Cancer Congress 2013"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdx796","article-title":"Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters - patient-centered end points in trials of maintenance therapy","volume":"29","author":"Friedlander","year":"2018","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ygyno.2015.12.027","article-title":"BRCA1\/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study","volume":"140","author":"Harter","year":"2016","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/igc.0000000000000602","article-title":"Pazopanib maintenance therapy in East Asian women with advanced epithelial ovarian cancer: results from AGO-OVAR16 and an East Asian study","volume":"28","author":"Mahner","year":"2018","journal-title":"International Journal of Gynecologic Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0015|cit15","unstructured":"Efficacy and safety of pazopanib monotherapy after first line chemotherapy in ovarian, fallopian tube, or primary peritoneal cancer www.clinicaltrials.gov\/ct2\/show\/NCT00866697"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0016|cit16","unstructured":"Efficacy and safety of pazopanib monotherapy after first-line chemotherapy in ovarian, fallopian tube, or primary peritoneal cancer in Asian women www.clinicaltrials.gov\/ct2\/show\/NCT01227928"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2019.08.024","article-title":"Overall survival results of AGO-OVAR16: a phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer","volume":"155","author":"Vergote","year":"2019","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"Abstract 5512","DOI":"10.1200\/jco.2013.31.15_suppl.5512","article-title":"Pazopanib (Paz) monotherapy in Asian women who have not progressed after first-line chemotherapy for advanced ovarian, Fallopian tube, or primary peritoneal carcinoma","volume":"31 Suppl","author":"Zang","year":"2013","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"30","key":"10.1002\/14651858.CD007930.pub3-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348.","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007930.pub3-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/S0090-8258(22)01250-1","article-title":"Clinical and molecular characteristics of AMBITION patients who received olaparib plus cediranib or olaparib plus durvalumab for homologous recombination repair mutated, platinum-resistant ovarian cancer (KGOG 3045) (032)","volume":"166","author":"Kim","year":"2022","journal-title":"Gynecologic Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1200\/JCO.2021.39.15_suppl.5520","article-title":"An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer (KGOG 3045, AMBITION)","volume":"39","author":"Lee","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD007930.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.3802\/jgo.2022.33.e45","article-title":"Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial","volume":"33","author":"Lee","year":"2022","journal-title":"Journal of Gynecologic Oncology"},{"issue":"8","key":"10.1002\/14651858.CD007930.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/jjco\/hyz085","article-title":"An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION","volume":"49","author":"Lee","year":"2019","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0024|cit24","unstructured":"An umbrella study of biomarker-driven targeted therapy In patients with platinum-resistant recurrent ovarian cancer (AMBITION) www.clinicaltrials.gov\/ct2\/show\/NCT03699449"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2017.35.15_suppl.5538","article-title":"Efficacy and long-term safety with bevacizumab included in neoadjuvant and adjuvant therapies in patients with advanced ovarian cancer: Results of the ANTHALYA trial\u00a0","volume":"35","author":"Joly","year":"2017","journal-title":"Journal of Clinical Oncology\u00a0"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0026|cit26","unstructured":"A study of bevacizumab (Avastin) in neoadjuvant therapy in participants with International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC\/IV ovarian, tubal, or peritoneal cancer, initially unresectable (ANTHALYA) www.clinicaltrials.gov\/ct2\/show\/NCT01739218"},{"issue":"6","key":"10.1002\/14651858.CD007930.pub3-BIB0027|cit27","first-page":"296","article-title":"860PD - Complete resection rate at interval debulking surgery after bevacizumab containing neoadjuvant therapy: primary objective of the ANTHALYA trial","volume":"27","author":"Rouzier","year":"2016","journal-title":"Annals of Oncology\u00a0"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejca.2016.09.036","article-title":"Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial","volume":"70","author":"Rouzier","year":"2017","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0029|cit29","first-page":"871","article-title":"Complete resection rate at interval debulking surgery after bevacizumab containing neoadjuvant therapy: primary objective of the ANTHALYA trial","volume":"26","author":"Rouzier","year":"2017","journal-title":"International Journal of Gynecological Cancer"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD007930.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"TPS5614","DOI":"10.1200\/jco.2014.32.15_suppl.tps5614","article-title":"A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc\/IV ovarian, tubal, or peritoneal adenocarcinoma, initially unresectable","volume":"32","author":"Rouzier","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0031|cit31","unstructured":"Apatinib combined with PLD vs PLD for platinum-resistant recurrent ovarian cancer (APPROVE) www.clinicaltrials.gov\/ct2\/show\/NCT04348032"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007930.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S0090-8258(21)00724-1","article-title":"Apatinib combined with pegylated liposomal doxorubicin (PLD) versus PLD for platinum-resistant recurrent ovarian cancer (APPROVE): a multicenter, randomized, controlled, open-label, phase II trial","volume":"162","author":"Wang","year":"2021","journal-title":"Gynecologic Oncology"},{"issue":"8","key":"10.1002\/14651858.CD007930.pub3-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1001\/jamaoncol.2022.2253","article-title":"Effect of Apatinib plus pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone on platinum-resistant recurrent ovarian cancer: the APPROVE randomized clinical trial","volume":"8","author":"Wang","year":"2022","journal-title":"JAMA Oncology"},{"issue":"7","key":"10.1002\/14651858.CD007930.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"e775","DOI":"10.1200\/JOP.2015.010470","article-title":"Is FDA-approved bevacizumab cost-effective when included in the treatment of platinum-resistant recurrent ovarian cancer?","volume":"12","author":"Chappell","year":"2016","journal-title":"Journal of Oncology Practice"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1016\/j.ygyno.2013.04.063","article-title":"Symptoms and adverse effects with chemotherapy + bevacizumab for platinum-resistant recurrent ovarian cancer: analysis of the phase III AURELIA trial","volume":"130","author":"Hilpert","year":"2013","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ygyno.2016.05.011","article-title":"Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer","volume":"142","author":"Husain","year":"2016","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0037|cit37","unstructured":"Kristensen G Berton-Rigaud D Hilpert F Reuss A Bover I Raspagliesi F Effect of bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC) with ascites: analysis of the AURELIA trial International Journal of Gynecological Cancer 2012 Conference Abstracts: 14th Biennial Meeting of the International Gynecologic Cancer Society"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0038|cit38","unstructured":"AURELIA: A study of Avastin (bevacizumab) added to chemotherapy in patients with platinum-resistant ovarian cancer www.clinicaltrials.gov\/ct2\/show\/NCT00976911"},{"issue":"32","key":"10.1002\/14651858.CD007930.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the candomized phase III AURELIA trial","volume":"33","author":"Poveda A","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"LBA5002","DOI":"10.1200\/jco.2012.30.18_suppl.lba5002","article-title":"AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT) resistant recurrent ovarian cancer (OC)","volume":"30","author":"Pujade-Lauraine","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"10.1002\/14651858.CD007930.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"35","key":"10.1002\/14651858.CD007930.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1200\/JCO.2014.60.0072","article-title":"Errata: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2016.11.006","article-title":"Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: subgroup analysis of the randomised phase III AURELIA trial","volume":"144","author":"Sorio","year":"2017","journal-title":"Gynecologic Oncology"},{"issue":"8","key":"10.1002\/14651858.CD007930.pub3-BIB0044|cit44","article-title":"Safety and efficacy of single-agent chemotherapy + bevacizumab in elderly patients with platinum-resistant recurrent ovarian cancer: subgroup analysis of Aurelia","volume":"23","author":"Sorio","year":"2013","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"Abstract 5542","DOI":"10.1200\/jco.2013.31.15_suppl.5542","article-title":"Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC)","volume":"31 Suppl","author":"Stockler","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2013.51.4240","article-title":"Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer","volume":"32","author":"Stockler","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD007930.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdw236","article-title":"Prognostic and predictive values of primary versus secondary platinum resistance for bevacizumab treatment in platinum resistant ovarian cancer in the AURELIA trial","volume":"27","author":"Trillsch","year":"2016","journal-title":"Annals of Oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007930.pub3-BIB0048|cit48","first-page":"S3","article-title":"Final overall survival (OS) results from AURELIA, an open-label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC)","volume":"49","author":"Witteveen","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ygyno.2017.02.039","article-title":"Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: a cost effectiveness analysis of the AURELIA trial","volume":"145","author":"Wysham","year":"2017","journal-title":"Gynecologic Oncology"},{"issue":"10","key":"10.1002\/14651858.CD007930.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(19)30515-7","article-title":"Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2\/ENGOT-ov24): a randomised, phase 2, superiority trial","volume":"20","author":"Mirza","year":"2019","journal-title":"Lancet Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD007930.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.2019.37.15_suppl.5505","article-title":"Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: a randomized controlled chemotherapy-free study-NSGO-AVANOVA2\/ENGOT-OV24","volume":"37","author":"Mirza","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD007930.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"TPS5607","DOI":"10.1200\/jco.2015.33.15_suppl.tps5607","article-title":"ENGOT-OV24-NSGO\/ AVANOVA: niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinumsensitive epithelial ovarian, fallopian tube, or peritoneal cancer","volume":"33","author":"Mirza","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1200\/JCO.2020.38.15_suppl.6012","article-title":"Final survival analysis of NSGO-AVANOVA2\/ ENGOT-OV24: combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer - a randomized controlled chemotherapy-free study","volume":"38","author":"Mirza","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0054|cit54","unstructured":"Niraparib versus niraparib-bevacizumab combination in women with platinum-sensitive epithelial ovarian cancer (AVANOVA) www.clinicaltrials.gov\/ct2\/show\/NCT02354131"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD007930.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"v896","DOI":"10.1093\/annonc\/mdz394.055","article-title":"BAROCCO: a randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC)","volume":"30","author":"Colombo","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD007930.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"viii357","DOI":"10.1093\/annonc\/mdy285.209","article-title":"BAROCCO: a randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer","volume":"29","author":"Colombo","year":"2018","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ygyno.2022.01.015","article-title":"Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer","volume":"164","author":"Colombo","year":"2022","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0058|cit58","unstructured":"Best approach in recurrent-ovarian-cancer-with cediranib-olaparib (BAROCCO) www.clinicaltrials.gov\/ct2\/show\/NCT03314740"},{"issue":"16 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1200\/JCO.2022.40.16_suppl.5554","article-title":"Immune tumor microenvironnement (iTME) post-neoadjuvant chemotherapy, beyond PD-L1: novel immune targets in ovarian cancer, data from the CHIVA trial, a GINECO\/ GINEGEPS study","volume":"40","author":"Blanc-Durand","year":"2022","journal-title":"Journal of Clinical Oncology\u00a0"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1200\/JCO.2019.37.15_suppl.5512","article-title":"Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: the CHIVA double-blind randomized phase II GINECO study","volume":"37","author":"Ferron","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD007930.pub3-BIB0061|cit61","first-page":"V1297","article-title":"The CHIVA study: a GINECO randomized double blind phase II trial of nintedanib versus placebo with the neo-adjuvant chemotherapy (NACT) strategy for patients (pts) with advanced unresectable ovarian cancer (OC). Report of the interval debulking surgery (IDS) safety outcome","volume":"27","author":"Ferron","year":"2016","journal-title":"Annals of Oncology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD007930.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"v415","DOI":"10.1093\/annonc\/mdz250.024","article-title":"Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study","volume":"30","author":"Lecuru","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0063|cit63","unstructured":"Vargatef in addition to first line chemotherapy with interval debulking surgery in patients with ovarian cancer (CHIVA) www.clinicaltrials.gov\/ct2\/show\/NCT01583322"},{"issue":"17","key":"10.1002\/14651858.CD007930.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","article-title":"CA-125 ELIMination rate constant K (KELIM) Is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial","volume":"26","author":"You","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0065|cit65","first-page":"1003","article-title":"Therapeutic effect of bevacizumab combined with paclitaxel and carboplatin on recurrent ovarian cancer","volume":"24","author":"Cong","year":"2019","journal-title":"Journal of the Balkan Union of Oncology (JBUON)"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1200\/JCO.2017.35.15_suppl.5532","article-title":"A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemictabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma","volume":"35\u00a0","author":"Duska","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ygyno.2019.10.014","article-title":"A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma","volume":"157","author":"Duska","year":"2020","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0068|cit68","unstructured":"A randomized open label phase II study of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of patients with persistent or relapsed epithelial ovarian, fallopian tube or primary peritoneal carcinoma www.clinicaltrials.gov\/ct2\/show\/NCT01610206"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"S1308","DOI":"10.1016\/j.annonc.2021.08.2109","article-title":"LBA32 Principal results of the EORTC-1508 trial: a phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma","volume":"32","author":"Banerjee","year":"2021","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0070|cit70","unstructured":"Anti-programmed cell death-1 ligand 1 (aPDL-1) antibody atezolizumab, bevacizumab and acetylsalicylic acid in recurrent platinum resistant ovarian cancer www.clinicaltrials.gov\/ct2\/show\/NCT02659384"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1200\/JCO.2017.35.15_suppl.5508","article-title":"Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC) (GEICO 1205\/NOVA TRIAL)","volume":"35","author":"Garcia Garcia","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007930.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/ijgc-2019-000256","article-title":"Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer","volume":"29","author":"Garcia Garcia","year":"2019","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0073|cit73","unstructured":"Neoadjuvant therapy in advanced ovarian cancer with Avastin (NOVA) www.clinicaltrials.gov\/ct2\/show\/NCT01847677"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007930.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2015.01.005","article-title":"A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213)","volume":"137","author":"Coleman R","year":"2015","journal-title":"Gynecologic Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007930.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0076|cit76","unstructured":"Carboplatin, paclitaxel and gemcitabine hydrochloride with or without bevacizumab after surgery in treating patients with recurrent ovarian epithelial, primary peritoneal, or fallopian tube cancer www.clinicaltrials.gov\/ct2\/show\/study\/NCT00565851"},{"issue":"9 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"IX81","DOI":"10.1016\/S0923-7534(20)32763-0","article-title":"Biomarker (BM) results from GOG-0218, a phase 3 trial of front-line bevacizumab (BV) + chemotherapy (CT) for ovarian cancer (OC)","volume":"23","author":"Birrer","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"S5 Abstract 7","DOI":"10.1016\/j.ygyno.2010.12.014","article-title":"Prospective investigation of risk factors for gastrointestinal adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: a Gynecologic Oncology Group study","volume":"120","author":"Burger","year":"2011","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0080|cit80","first-page":"Abstr 978PD vii","article-title":"Safety and subgroup efficacy analyses in GOG218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or fallopian tube cancer (FTC)","volume":"21","author":"Burger","year":"2010","journal-title":"Annals of Oncology"},{"issue":"Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"Abstr LBA1","DOI":"10.1200\/jco.2010.28.18_suppl.lba1","article-title":"Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC)","volume":"28","author":"Burger","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ygyno.2013.07.100","article-title":"Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"131","author":"Burger","year":"2013","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"Abstract 5023","DOI":"10.1200\/jco.2011.29.15_suppl.5023","article-title":"Independent radiologic review of GOG218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian (EOC), primary peritoneal (PPC) or Fallopian tube cancer (FTC)","volume":"29","author":"Burger","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ygyno.2011.12.070","article-title":"A practical prediction model for determining bevacizumab response and toxicity in the treatment of advanced ovarian and peritoneal cancers - an analysis of GOG 218","volume":"125","author":"Chan","year":"2012","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2012.06.002","article-title":"Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study","volume":"126","author":"Chase","year":"2012","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.1016\/j.ygyno.2013.04.113","article-title":"Prognostic significance of ethnicity and age in advanced stage ovarian cancer: an analysis of GOG 218","volume":"130","author":"Du Pont","year":"2013","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.3816\/COC.2010.n.020","article-title":"Addition of bevacizumab to paclitaxel\/carboplatin in first-line management of advanced ovarian cancer: results of the GOG 0218 phase III study (Meeting Highlights: ASCO 2010)","volume":"3","author":"Garcia","year":"2010","journal-title":"Clinical Ovarian Cancer"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ygyno.2010.08.016","article-title":"Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer","volume":"119","author":"Han","year":"2010","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0959-8049(11)70122-8","article-title":"Quality of life outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a gynecologic oncology group study","volume":"47","author":"Monk","year":"2011","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2012.11.038","article-title":"Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study","volume":"128","author":"Monk","year":"2013","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0091|cit91","unstructured":"Carboplatin and paclitaxel with or without bevacizumab in treating patients with stage III or stage IV ovarian epithelial, primary peritoneal, or fallopian tube cancer www.clinicaltrials.gov\/ct2\/show\/NCT00262847"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ygyno.2017.07.121","article-title":"Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: an ancillary data analysis of the NRG Oncology\/Gynecologic Oncology Group (GOG-0218) study","volume":"147","author":"Phippen","year":"2017","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"e33\u00a0","DOI":"10.1016\/j.ygyno.2013.04.139","article-title":"Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab","volume":"130","author":"Randall","year":"2013","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/j.ygyno.2013.04.346","article-title":"Time from completion of chemotherapy to disease progression as a clinically relevant endpoint in women with epithelial ovarian, primary peritoneal, and fallopian tube cancers treated with and without bevacizumab","volume":"130","author":"Randall","year":"2013","journal-title":"Gynecologic Oncology"},{"issue":"26","key":"10.1002\/14651858.CD007930.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD007930.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1200\/JCO.2022.40.16_suppl.5553","article-title":"Identification of patients with ovarian cancer who are experiencing the highest benefit from bevacizumab in first-line setting based on their tumor intrinsic chemosensitivity (KELIM): GOG-0218 validation study","volume":"40","author":"You","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ygyno.2019.03.256","article-title":"An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC\/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor","volume":"153","author":"Gore","year":"2019","journal-title":"Gynecologic Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD007930.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1200\/jco.2015.33.15_suppl.5528","article-title":"Multicentre trial of carboplatin\/paclitaxel versus oxaliplatin\/capecitabine, each with\/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC)","volume":"33","author":"Gore","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0099|cit99","unstructured":"Carboplatin and paclitaxel or oxaliplatin and capecitabine with or without bevacizumab as first-line therapy in treating patients with newly diagnosed stage II-IV or recurrent stage I epithelial ovarian or fallopian tube cancer www.clinicaltrials.gov\/ct2\/show\/NCT01081262"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0100|cit100","doi-asserted-by":"crossref","unstructured":"Gotlieb W H Amant F Advani S Goswami C Hirte H Provencher D Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study Lancet Oncology 2012 13 154 62","DOI":"10.1016\/S1470-2045(11)70338-2"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0101|cit101","unstructured":"Study of the effect of intravenous AVE0005 (VEGF Trap) in advanced ovarian cancer patients with recurrent symptomatic malignant ascites www.clinicaltrials.gov\/ct2\/show\/study\/NCT00327444"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0102|cit102","unstructured":"Vergote I Amant F Advani F Goswami C Hirte H Intravenous aflibercept (VEGF Trap) for the treatment of recurrent symptomatic malignant ascites Personal communication (Abstract to subsequent full published version of the study, received from authors prior to original version of the review)"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0103|cit103","unstructured":"Vergote I Amant F Advani F Goswani C Hirte H Provencher D Aflibercept (VEGF Trap) in advanced ovarian cancer patients with recurrent symptomatic malignant ascites: results of a randomized, double-blind, placebo-controlled study 16th International Meeting of the European Society of Gynaecological Oncology; 2009 Oct 11-14; Belgrade, Serbia 2009 Abstract 1428"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0104|cit104","first-page":"Suppl 2","article-title":"Aflibercept (VEGF Trap) in advanced ovarian cancer patients with recurrent symptomatic malignant ascites: results of a randomized, double-blind, placebo-controlled study","volume":"19","author":"Vergote","year":"2009","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"100155","DOI":"10.1016\/j.ctarc.2019.100155","article-title":"Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer","volume":"21","author":"Gupta","year":"2019","journal-title":"Cancer Treatment and Research Communications"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0106|cit106","unstructured":"Trial protocol: cyclophosphamide with or without celecoxib in treating patients with recurrent or persistent ovarian epithelial, fallopian tube, or primary peritoneal cancer www.clinicaltrials.gov\/ct2\/show\/NCT00538031"},{"issue":"5","key":"10.1002\/14651858.CD007930.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/cam4.376","article-title":"Paclitaxel\/carboplatin with or without sorafenib in the first-line treatment of patients with stage III\/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute","volume":"4","author":"Hainsworth J","year":"2015","journal-title":"Cancer Medicine"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD007930.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"TPS257","DOI":"10.1200\/jco.2010.28.15_suppl.tps257","article-title":"A randomized phase II study of paclitaxel\/carboplatin with or without sorafenib in the first-line treatment of patients with stage III\/IV epithelial ovarian cancer","volume":"28","author":"Hainsworth","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0109|cit109","unstructured":"Paclitaxel and carboplatin with or without sorafenib in the first-line treatment of patients with ovarian cancer www.clinicaltrials.gov\/ct2\/show\/NCT00390611"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/jco.2013.31.15_suppl.5513","article-title":"Paclitaxel\/carboplatin with or without sorafenib in the first-line treatment of patients with stage III\/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute","volume":"31","author":"Thompson","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007930.pub3-BIB0111|cit111","first-page":"E99","article-title":"A randomized, double-blind phase 2 trial of maintenance sorafenib in epithelial ovarian or primary peritoneal cancer","volume":"22","author":"Herzog","year":"2012","journal-title":"International Journal of Gynecological Cancer"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2013.04.011","article-title":"A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma","volume":"130","author":"Herzog","year":"2013","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0113|cit113","unstructured":"Comparison of nexavar\/placebo as maintenance therapy for patients with advanced ovarian or primary peritoneal cancer www.clinicaltrials.gov\/ct2\/show\/NCT00791778"},{"issue":"10023","key":"10.1002\/14651858.CD007930.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"100043","DOI":"10.1016\/j.esmoop.2020.100043","article-title":"Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial","volume":"6","author":"Ledermann","year":"2021","journal-title":"ESMO Open"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0116|cit116","unstructured":"Ledermann JA Perren T Raja F A Perren T J Embleton A Rustin GJS Randomised double-blind phase iii trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial NCRI Cancer Conference (www.abstracts.ncri.org.uk\/abstract\/) 2013"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007930.pub3-BIB0117|cit117","first-page":"S5","article-title":"LBA10: Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial","volume":"49","author":"Ledermann","year":"2013","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0118|cit118","unstructured":"A randomised, placebo-controlled, trial of concurrent cediranib [AZD2171] (with platinum-based chemotherapy) and concurrent and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer www.clinicaltrials.gov\/ct2\/show\/NCT00532194"},{"issue":"7","key":"10.1002\/14651858.CD007930.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/bjc.2011.334","article-title":"Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer","volume":"105","author":"Raja","year":"2011","journal-title":"British Journal of Cancer"},{"issue":"8","key":"10.1002\/14651858.CD007930.pub3-BIB0120|cit120","first-page":"Suppl 1","article-title":"Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial","volume":"23","author":"Raja","year":"2013","journal-title":"International Journal of Gynecological Cancer"},{"issue":"14","key":"10.1002\/14651858.CD007930.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1002\/cncr.30657","article-title":"Quality of life with cediranib in relapsed ovarian cancer: the ICON6 phase 3 randomized clinical trial","volume":"123","author":"Stark","year":"2017","journal-title":"Cancer"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD007930.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1200\/jco.2015.33.15_suppl.5548","article-title":"Exploratory outcome analyses according to stage and residual disease in the ICON7 trial of frontline carboplatin\/paclitaxel (CP) +\/- bevacizumab (BEV) for ovarian cancer (OC)","volume":"33","author":"Gonzalez-Martin","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD007930.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jval.2016.01.013","article-title":"The Cost-effectiveness of bevacizumab in advanced ovarian cancer using evidence from the ICON7 Trial","volume":"19","author":"Hinde","year":"2016","journal-title":"Value Health"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0124|cit124","unstructured":"ICON7 - a randomised two-arm, multi-centre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer [abstract] Proceedings of the Annual Meeting of the British Gynaecological Cancer Society, Manchester, UK 1 92"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0125|cit125","unstructured":"ICON7 - a randomised, two-arm, multi-centre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer www.isrctn.com\/ISRCTN91273375"},{"issue":"14","key":"10.1002\/14651858.CD007930.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1158\/1078-0432.CCR-16-2196","article-title":"Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes","volume":"23","author":"Kommoss","year":"2017","journal-title":"Clinical Cancer Research"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"LBA5006","DOI":"10.1200\/jco.2011.29.18_suppl.lba5006","article-title":"Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer","volume":"29","author":"Kristensen","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12916-022-02270-y","article-title":"c-MET\/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial","volume":"20","author":"Morgan","year":"2022","journal-title":"BMC Medicine"},{"issue":"8","key":"10.1002\/14651858.CD007930.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza A","year":"2015","journal-title":"Lancet Oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007930.pub3-BIB0130|cit130","first-page":"S4","article-title":"LBA6: ICON7: final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer","volume":"49","author":"Oza","year":"2013","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0131|cit131","unstructured":"Perren T Swart AM Pfisterer J Ledermann J Lortholary A ICON7: A phase III Gynaecologic Cancer InterGroup (GCIG) trial of adding bevacizumab to standard chemotherapy in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer Powerpoint Presentation from European Society for Medical Oncology 2010 2010"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD007930.pub3-BIB0132|cit132","first-page":"LBA4","article-title":"ICON7: a phase III randomised Gynaecologic Cancer Intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC)","volume":"21","author":"Perren","year":"2010","journal-title":"Annals of Oncology"},{"issue":"26","key":"10.1002\/14651858.CD007930.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"8\u00a0","key":"10.1002\/14651858.CD007930.pub3-BIB0134|cit134","first-page":"Suppl 1","article-title":"ICON7: final overall survival results in the GCIG phase III randomised trial of bevacizumab in newly diagnosed ovarian cancer","volume":"23","author":"Pujade-Lauraine","year":"2013","journal-title":"International Journal of Gynecological Cancer"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007930.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0959-8049(11)70121-6","article-title":"Quality of life in the ICON7 GCIG phase III randomised clinical trial","volume":"47","author":"Stark","year":"2011","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0136|cit136","doi-asserted-by":"crossref","unstructured":"Stark D Nankivell M Pujade-Lauraine E Kristensen G Elit L Stockler M Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial Lancet Oncology 2013 14 3 236 43","DOI":"10.1016\/S1470-2045(12)70567-3"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/bjc.2016.194","article-title":"Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies tie2 AS a biomarker of vascular progression on bevacizumab","volume":"115","author":"Zhou","year":"2016","journal-title":"British Journal of Cancer"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1200\/jco.2012.30.15_suppl.5072","article-title":"Exposure-response relationship of open-label (OL) AMG 386 monotherapy in patients (pts) with recurrent ovarian cancer","volume":"30","author":"Karlan","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD007930.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1200\/jco.2010.28.15_suppl.5000","article-title":"Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma","volume":"28","author":"Karlan","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD007930.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1200\/JCO.2010.34.3178","article-title":"Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer","volume":"30","author":"Karlan","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1200\/jco.2010.28.15_suppl.5042","article-title":"Exposure-response relationships of AMG 386 in combination with weekly paclitaxel in advanced ovarian cancer: Population pharmacokinetic\/pharmacodynamic (PK\/PD) modelling to facilitate phase III dose selection","volume":"28","author":"Lu","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD007930.pub3-BIB0142|cit142","first-page":"viii308","article-title":"Exposure-response relationships of AMG 386 in combination with weekly paclitaxel in advanced ovarian cancer: facilitation of phase 3 dose selection by population pharmacokinetic\/pharmacodynamic modelling","volume":"21","author":"Lu","year":"2010","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD007930.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00280-011-1787-5","article-title":"Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection","volume":"69","author":"Lu","year":"2012","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0144|cit144","unstructured":"Phase 2, AMG 386 (20060342) in combination with paclitaxel for subjects with advanced recurrent epithelial ovarian or primary peritoneal cancer www.clinicaltrials.gov\/ct2\/show\/NCT00479817"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007930.pub3-BIB0145|cit145","first-page":"122","article-title":"AMG 386 plus weekly paclitaxel for the treatment of advanced ovarian cancer: a randomized, double-blind, placebo-controlled phase 2 study","volume":"6","author":"Richardson","year":"2010","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD007930.pub3-BIB0146|cit146","first-page":"viii 305","article-title":"A randomised, double-blind, placebo-controlled phase 2 study of AMG 386 plus weekly paclitaxel in patients (pts) with advanced ovarian cancer","volume":"21","author":"Vergote","year":"2010","journal-title":"Annals of Oncology"},{"issue":"28","key":"10.1002\/14651858.CD007930.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2010.33.5208","article-title":"Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer","volume":"29","author":"Ledermann","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD007930.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/jco.2009.27.15_suppl.5501","article-title":"A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC)","volume":"2","author":"Ledermann","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0149|cit149","unstructured":"A randomized placebo-controlled Phase II study of continuous maintenance treatment with BIBF 1120 following chemotherapy in patients with relapsed ovarian cancer clinicaltrials.gov\/ct2\/show\/NCT00710762"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0150|cit150","first-page":"3","article-title":"Study on the short-term efficacy and safety of bevacizumab combined with chemotherapy for platinum-sensitive recurrent ovarian cancer","volume":"125","author":"Li","year":"2019","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"issue":"5","key":"10.1002\/14651858.CD007930.pub3-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"491","DOI":"10.19526\/j.cnki.1005-8915.20210511","article-title":"Efficacy of bevacizumab combined with albumin binding paclitaxel in patients with platinum-resistant relapsed and metastatic ovarian cancer and effect on immune function","volume":"28","author":"Li","year":"2021","journal-title":"Chinese Journal of Pharmaceutical Biotechnology\u00a0"},{"issue":"6","key":"10.1002\/14651858.CD007930.pub3-BIB0152|cit152","first-page":"2303","article-title":"Efficacy of bevacizumab combined with albumin-bound paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer","volume":"24","author":"Liu","year":"2019","journal-title":"Journal of B.U.ON."},{"issue":"18","key":"10.1002\/14651858.CD007930.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"LBA5500","DOI":"10.1200\/jco.2014.32.18_suppl.lba5500","article-title":"A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer","volume":"32","author":"Liu","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD007930.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD007930.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/annonc\/mdz018","article-title":"Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer","volume":"30","author":"Liu","year":"2019","journal-title":"Annals of Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD007930.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1200\/JCO.2017.35.15_suppl.5535","article-title":"Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer","volume":"35","author":"Liu","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0157|cit157","unstructured":"Cediranib maleate and olaparib in treating patients with recurrent ovarian epithelial cancer, fallopian tube cancer, peritoneal cancer, or recurrent triple-negative breast cancer www.clinicaltrials.gov\/ct2\/show\/NCT01116648"},{"issue":"8","key":"10.1002\/14651858.CD007930.pub3-BIB0158|cit158","first-page":"818","article-title":"Evaluation of the short-term efficacy and safety of bevacizumab combined with doxorubicin liposomes in the treatment of patients with platinum-resistant recurrent epithelial ovarian cancer","volume":"28","author":"Liu","year":"2021","journal-title":"Chinese Journal of Cancer Biotherapy"},{"issue":"15 suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1200\/JCO.2020.38.15_suppl.6003","article-title":"A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer","volume":"38","author":"Liu","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"10.1002\/14651858.CD007930.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.21.02011","article-title":"Olaparib with or without cediranib versus platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (NRG-GY004): a randomized, open-label, phase III trial","volume":"40","author":"Liu","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0161|cit161","unstructured":"Testing the use of a single drug (olaparib) or the combination of two drugs (cediranib and olaparib) compared to the usual chemotherapy for women with platinum sensitive ovarian, fallopian tube, or primary peritoneal cancer www.clinicaltrials.gov\/ct2\/show\/NCT02446600"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD007930.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"S1309","DOI":"10.1016\/j.annonc.2021.08.2111","article-title":"Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004","volume":"32","author":"Swisher","year":"2021","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ygyno.2018.12.008","article-title":"A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: an NRG Oncology\/Gynecologic Oncology Group study","volume":"152","author":"Matulonis","year":"2019","journal-title":"Gynecolic Oncololgy"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0164|cit164","unstructured":"Cabozantinib or paclitaxel in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer www.clinicaltrials.gov\/ct2\/show\/NCT01716715"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1186\/s12885-018-5198-4","article-title":"Randomized phase II study of the PDGFR\u03b1 antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer","volume":"18","author":"McGuire","year":"2018","journal-title":"BMC Cancer"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"TPS256","DOI":"10.1200\/jco.2010.28.15_suppl.tps256","article-title":"Randomized phase II trial of pegylated liposomal doxorubicin (PLD) with or without anti-platelet-derived growth factor receptor-alpha (PDGFR-alpha) monoclonal antibody IMC-3G3 in platinum-refractory\/resistant advanced ovarian cancer","volume":"28","author":"McGuire","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0167|cit167","unstructured":"A study of Liposomal Doxorubicin with or without IMC-3G3 in platinum-refractory or resistant advanced ovarian cancer www.clinicaltrials.gov\/ct2\/show\/NCT00913835"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"vi296","DOI":"10.1093\/annonc\/mdw374.51","article-title":"METRO-BIBF Phase II, randomised, placebo controlled, multicentre, feasibility study of low dose (metronomic) cyclophosphamide (MCy) with and without nintedanib in advanced ovarian cancer (AOC)","volume":"27","author":"Hall","year":"2016","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ygyno.2020.09.048","article-title":"A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer","volume":"159","author":"Hall","year":"2020","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0170|cit170","unstructured":"Low dose cyclophosphamide +\/-- nintedanib in advanced ovarian cancer (METRO-BIBF) www.clinicaltrials.gov\/ct2\/show\/NCT01610869"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0171|cit171","unstructured":"Weekly paclitaxel with or without pazopanib in platinum resistant or refractory ovarian cancer (MITO-11) www.clinicaltrials.gov\/ct2\/show\/NCT01644825)"},{"issue":"5","key":"10.1002\/14651858.CD007930.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"Abstract 5503","DOI":"10.1200\/jco.2014.32.15_suppl.5503","article-title":"MITO-11: A randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC)","volume":"32","author":"Pignata","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0174|cit174","unstructured":"Bevacizumab beyond progression in platinum sensitive ovarian cancer (MITO16MANGO2b) www.clinicaltrials.gov\/ct2\/show\/NCT01802749"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(20)30637-9","article-title":"Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial","volume":"22","author":"Pignata","year":"2021","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0176|cit176","first-page":"A127","article-title":"A randomised phase II study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear cell carcinoma of the ovary or endometrium (NICCC\/ENGOT-OV36)","volume":"30","author":"Glasspool","year":"2020","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0177|cit177","unstructured":"Study of nintedanib compared to chemotherapy in patients with recurrent clear cell carcinoma of the ovary or Eedometrium (NiCCC) www.clinicaltrials.gov\/ct2\/show\/NCT02866370"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007930.pub3-BIB0178|cit178","first-page":"A10","article-title":"Phase II trial evaluating efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer","volume":"30","author":"Nishikawa","year":"2020","journal-title":"International Journal of Gynecological Cancer"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/cas.15185","article-title":"Efficacy and safety of standard of care with\/without bevacizumab for platinum-resistant ovarian\/fallopian tube\/peritoneal cancer previously treated with bevacizumab: the Japanese Gynecologic Oncology Group study JGOG3023","volume":"113","author":"Shoji","year":"2022","journal-title":"Cancer Science\u00a0"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ygyno.2012.03.038","article-title":"Results from a 2nd interim os analysis in oceans: a randomized phase 3 trial of gemcitabine (G), carboplatin (C) and bevacizumab (BV) followed by BV to disease progression in patients with platinum-sensitive recurrent epithelial ovarian (OC), primary peritoneal (PPC), or fallopian tube cancer (FTC)","volume":"125","author":"Aghajanian","year":"2012","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0959-8049(11)70104-6","article-title":"Efficacy in patient subgroups in OCEANS, a randomized, doubleblinded, placebo-controlled, phase 3 trial of chemotherapy +\/- bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian (OC), primary peritoneal (PPC), or fallopian tube cancer (FTC)","volume":"47","author":"Aghajanian","year":"2011","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1200\/jco.2012.30.15_suppl.5054","article-title":"An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0184|cit184","first-page":"S11","article-title":"Oceans: A randomized, Double-blinded, Placebo-controlled, Phase III trial of chemotherapy+\/- bevacizumab (BEV) in platinum-sensitive recurrent epithelial ovarian cancers (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)","volume":"21","author":"Aghajanian","year":"2011","journal-title":"International Journal of Gynecological Cancer"},{"issue":"18","key":"10.1002\/14651858.CD007930.pub3-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"LBA5007","DOI":"10.1200\/jco.2011.29.18_suppl.lba5007","article-title":"OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)","volume":"29","author":"Aghajanian","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD007930.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"LBA5007","DOI":"10.1200\/jco.2011.29.18_suppl.lba5007","article-title":"OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)","volume":"29","author":"Aghajanian","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecologic Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007930.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ygyno.2014.03.157","article-title":"Final analysis of overall survival in OCEANS, a randomized phase III trial of gemcitabine, carboplatin, and bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive recurrent ovarian cancer","volume":"133","author":"Aghajanian","year":"2014","journal-title":"Gynecologic Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007930.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.ygyno.2011.12.069","article-title":"Independent radiologic review of OCEANS, a phase III trial of carboplatin, gemcitabine, and bevacizumab or placebo for the treatment of platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"125","author":"Aghajanian","year":"2012","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0190|cit190","unstructured":"Aghajanian C Nycum L Chan JK Husain A Yi J Blank SV CA-125 in oceans: phase 3 randomized study of gemcitabine\/carboplatin + bevacizumab (GC+BV) or placebo (GC+PL) in platinum-sensitive recurrent ovarian cancer 14th Biennial Meeting of the International Gynecologic Cancer Society 2012"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0191|cit191","unstructured":"A study of carboplatin and gemcitabine plus bevacizumab in patients with ovary, peritoneal, or fallopian tube carcinoma (OCEANS) www.clinicaltrials.gov\/ct2\/show\/NCT00434642"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"e041463","DOI":"10.1136\/bmjopen-2020-041463","article-title":"Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol","volume":"11","author":"Mansouri","year":"2021","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0193|cit193","unstructured":"Olaparib +\/- cediranib or chemotherapy in patients with platinum-resistant ovarian cancer (OCTOVA) www.clinicaltrials.gov\/ct2\/show\/NCT03117933"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD007930.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"S725","DOI":"10.1016\/j.annonc.2021.08.1165","article-title":"Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)","volume":"32","author":"Nicum","year":"2021","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0195|cit195","doi-asserted-by":"crossref","unstructured":"A randomized phase II study investigating the addition of the specific cox-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian fallopian tube or primary peritoneal carcinomas www.isrctn.com\/ISRCTN30851756 https:\/\/doi.org\/10.1186\/ISRCTN30851756","DOI":"10.1186\/ISRCTN30851756"},{"issue":"11","key":"10.1002\/14651858.CD007930.pub3-BIB0196|cit196","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1093\/annonc\/mds107","article-title":"A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, fallopian tube or primary peritoneal carcinomas: the DoCaCel study","volume":"23","author":"Reyners","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0197|cit197","unstructured":"Paclitaxel with or without pazopanib hydrochloride in treating patients with persistent or recurrent ovarian epithelial, fallopian tube, or peritoneal cavity cancer www.clinicaltrials.gov\/ct2\/show\/NCT01468909"},{"issue":"9","key":"10.1002\/14651858.CD007930.pub3-BIB0198|cit198","first-page":"17","article-title":"A randomized placebo controlled phase IIB trial of weekly paclitaxel plus\/minus pazopanib in persistent or recurrent ovarian cancer","volume":"24","author":"Richardson","year":"2014","journal-title":"International Journal of Gynecological Cancer"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamaoncol.2017.4218","article-title":"Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer: a randomized clinical trial","volume":"4","author":"Richardson","year":"2018","journal-title":"JAMA Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0200|cit200","unstructured":"Evaluation of weekly ixabepilone with or without biweekly bevacizumab www.clinicaltrials.gov\/ct2\/show\/NCT03093155"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007930.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0090-8258(21)00753-8","article-title":"Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian\/fallopian tube\/primary peritoneal cancer","volume":"162","author":"Roque","year":"2021","journal-title":"Gynecologic Oncology"},{"issue":"12","key":"10.1002\/14651858.CD007930.pub3-BIB0202|cit202","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1038\/s41416-022-01717-6","article-title":"Randomised phase II trial of weekly ixabepilone \u00b1 biweekly bevacizumab for platinum-resistant or refractory ovarian\/fallopian tube\/primary peritoneal cancer","volume":"126","author":"Roque","year":"2022","journal-title":"British Journal of Cancer"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1200\/JCO.2020.38.15_suppl.6048","article-title":"Quality of life, vascular endothelial growth factor inhibition, and survival outcomes with combination oral metronomic therapy in platinum refractory epithelial ovarian carcinoma: results from a randomized study","volume":"38","author":"Sharma","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ygyno.2021.05.025","article-title":"Pazopanib based oral metronomic therapy for platinum resistant\/refractory epithelial ovarian cancer: a phase II, open label, randomized, controlled trial","volume":"162","author":"Sharma","year":"2021","journal-title":"Gynecologic Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/jco.2012.30.15_suppl.5015","article-title":"Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D-V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904","volume":"30","author":"Coleman","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD007930.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.ejca.2014.03.005","article-title":"Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904","volume":"50","author":"Coleman","year":"2014","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0207|cit207","unstructured":"Docetaxel with or without vandetanib in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer www.clinicaltrials.gov\/ct2\/show\/NCT00872989"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0208|cit208","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ygyno.2022.06.022","article-title":"Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: the GINECO randomized phase II TAPAZ study","volume":"166","author":"Joly","year":"2022\u00a0","journal-title":"Gynecology Oncology\u00a0"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007930.pub3-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"S611","DOI":"10.1016\/j.annonc.2020.08.947","article-title":"Paclitaxel with or without pazopanib in ovarian cancer patients with relapse during bevacizumab maintenance therapy: the GINECO randomized phase II TAPAZ study","volume":"31","author":"Joly Lobbedez","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0210|cit210","unstructured":"Paclitaxel\/pazopanib for platinum resistant\/refractory ovarian cancer (TAPAZ) www.clinicaltrials.gov\/ct2\/show\/NCT02383251"},{"issue":"9","key":"10.1002\/14651858.CD007930.pub3-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S1470-2045(18)30372-3","article-title":"Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Chekerov","year":"2018","journal-title":"Lancet Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"e15548","DOI":"10.1200\/jco.2011.29.15_suppl.e15548","article-title":"A randomized, double-blind, placebo-controlled, multicenter phase II study to compare the efficacy and safety of sorafenib added to standard treatment with topotecan to standard treatment alone in patients with platinum-resistant recurrent ovarian cancer (TRIAS): results of a NOGGO-AGO intergroup pilot-study","volume":"29","author":"Khalfaoui","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0213|cit213","unstructured":"Efficacy and safety study of sorafenib with topotecan in patients with platinum-resistant recurrent ovarian cancer (TRIAS 2009) www.clinicaltrials.gov\/ct2\/show\/NCT01047891"},{"issue":"6","key":"10.1002\/14651858.CD007930.pub3-BIB0214|cit214","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/annonc\/mdw147","article-title":"Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)","volume":"27","author":"Fujiwara","year":"2016","journal-title":"Annals of Oncology"},{"issue":"9 Suppl 4","key":"10.1002\/14651858.CD007930.pub3-BIB0215|cit215","first-page":"231","article-title":"A subgroup analysis of trinova-1: weekly trebananib or placebo plus paclitaxel in Asian women with recurrent ovarian cancer","volume":"24","author":"Fujiwara","year":"2014","journal-title":"International Journal of Gynecological Cancer"},{"issue":"8","key":"10.1002\/14651858.CD007930.pub3-BIB0216|cit216","first-page":"49","article-title":"A phase 3, randomized, double-blind trial of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer: Trinova-1","volume":"23","author":"Monk","year":"2013","journal-title":"International Journal of Gynecological Cancer"},{"issue":"8","key":"10.1002\/14651858.CD007930.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","article-title":"Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Monk","year":"2014","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2016.07.112","article-title":"Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free survival-2","volume":"143","author":"Monk","year":"2016","journal-title":"Gynecologic Oncology"},{"issue":"15","key":"10.1002\/14651858.CD007930.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1200\/jco.2015.33.15_suppl.5503","article-title":"Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: results from the phase III TRINOVA1 study","volume":"33","author":"Monk","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007930.pub3-BIB0220|cit220","first-page":"S18","article-title":"LBA41: A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1","volume":"49","author":"Monk","year":"2013","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0221|cit221","unstructured":"TRINOVA-1: a study of AMG 386 or placebo, in combination with weekly paclitaxel chemotherapy, as treatment for ovarian cancer, primary peritoneal cancer and fallopian tube cancer www.clinicaltrials.gov\/ct2\/show\/NCT01204749"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007930.pub3-BIB0222|cit222","first-page":"97","article-title":"ENGOT-ov-6\/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer","volume":"25","author":"Marth","year":"2015","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2016.09.004","article-title":"ENGOT-ov-6\/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer","volume":"70","author":"Marth","year":"2017","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0224|cit224","unstructured":"AMG 386 (Trebananib) in ovarian cancer (TRINOVA-2) www.clinicaltrials.gov\/ct2\/show\/NCT01281254"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0225|cit225","unstructured":"TRINOVA-3: a study of AMG 386 or AMG 386 placebo in combination with paclitaxel and carboplatin to treat ovarian cancer www.clinicaltrials.gov\/ct2\/show\/NCT01493505"},{"issue":"6","key":"10.1002\/14651858.CD007930.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(19)30178-0","article-title":"Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3\/ENGOT-ov2\/GOG-3001): a randomised, double-blind, phase 3 trial","volume":"20","author":"Vergote","year":"2019","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0227|cit227","unstructured":"Clinical study in treatment of malignant ascites of ovarian cancer with intraperitoneal injection bevacizumab combined with intraperitoneal hyperthermic perfusion chemotherapy www.clinicaltrials.gov\/ct2\/show\/NCT01838538"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1200\/jco.2013.31.15_suppl.5558","article-title":"Clinical study of intraperitoneal injection bevacizumab (BV) combined with intraperitoneal hyperthermic perfusion chemotherapy (CT) in treatment of malignant ascites of ovarian cancer (OC)","volume":"31 Suppl","author":"Zhao","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12032-014-0292-1","article-title":"Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial","volume":"32","author":"Zhao","year":"2015","journal-title":"Medical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD007930.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1001\/jamaoncol.2020.4574","article-title":"Effect of weekly paclitaxel with or without bevacizumab on progression-free rate among patients with relapsed ovarian sex cord-stromal tumors: the ALIENOR\/ENGOT-ov7 randomized clinical trial","volume":"6","author":"Ray-Coquard","year":"2020","journal-title":"JAMA Oncology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD007930.pub3-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"viii333","DOI":"10.1093\/annonc\/mdy285.143","article-title":"Alienor\/ENGOT-ov7 randomized trial exploring weekly paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian sex cord tumors (SCT) in relapse","volume":"29","author":"Ray-Coquard","year":"2018","journal-title":"Annals of Oncology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD007930.pub3-BIB0232|cit232","first-page":"S23","article-title":"Combination therapy with sorafenib and bevacizumab is active in epithelail ovarian cancer","volume":"108","author":"Azad","year":"2008","journal-title":"Gynecologic Oncology"},{"issue":"9","key":"10.1002\/14651858.CD007930.pub3-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/annonc\/mds003","article-title":"A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy","volume":"23","author":"Baumann","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0234|cit234","unstructured":"Randomized multicenter trial with SU11248 evaluating dosage, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor www.clinicaltrials.gov\/ct2\/show\/NCT00543049"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0235|cit235","unstructured":"Evaluation of optimal treatment duration of bevacizumab combination with standard chemotherapy in patients with ovarian cancer (BOOST) www.clinicaltrials.gov\/ct2\/show\/study\/NCT01462890"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cncr.28421","article-title":"Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group","volume":"120","author":"Brown","year":"2014","journal-title":"Cancer\u00a0"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3802\/jgo.2010.21.1.3","article-title":"Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies","volume":"21","author":"Burger","year":"2010","journal-title":"Journal of Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2012.07.126","article-title":"A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma","volume":"128","author":"Campos","year":"2013","journal-title":"Gynecologic Oncology\u00a0"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0239|cit239","first-page":"Supp 1","article-title":"Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin +\/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712)","volume":"23","author":"Chan","year":"2013","journal-title":"International Journal of Gynecological Cancer"},{"issue":"8","key":"10.1002\/14651858.CD007930.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0241|cit241","unstructured":"Paclitaxel and carboplatin with or without bevacizumab in treating patients with stage III or stage IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer clinicaltrials.gov\/ct2\/show\/NCT01167712"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2011.11.021","article-title":"A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites","volume":"125","author":"Colombo","year":"2012","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0243|cit243","unstructured":"Durvalumab Ttreatment in combination with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib treatment in advanced ovarian cancer patients (DUO-O) www.clinicaltrials.gov\/ct2\/show\/study\/NCT03737643"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007930.pub3-BIB0244|cit244","doi-asserted-by":"publisher","first-page":"S170","DOI":"10.1016\/S0090-8258(22)01551-7","article-title":"A randomized phase III trial of durvalumab with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer (DUO-O): updated trial endpoint and inclusion of China cohort (329)","volume":"166","author":"Okamoto","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0245|cit245","unstructured":"Pembrolizumab\/placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer (MK-3475-B96\/KEYNOTE-B96\/ENGOT-ov65) www.clinicaltrials.gov\/ct2\/show\/study\/NCT05116189"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD007930.pub3-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"TPS6097","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS6097","article-title":"Clinical trial in progress: pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701\/GOG-3018)","volume":"38","author":"Arend","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD007930.pub3-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"TPS5599","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5599","article-title":"Clinical trial in progress: pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111- 701\/GOG-3018)","volume":"39","author":"Arend","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1002\/14651858.CD007930.pub3-BIB0248|cit248","doi-asserted-by":"publisher","first-page":"TPS5606","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5606","article-title":"Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701\/GOG-3018)","volume":"40","author":"Penson","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ygyno.2013.09.032","article-title":"Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer","volume":"131","author":"Hagemann","year":"2013","journal-title":"Gynecologic Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007930.pub3-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s10637-013-0011-3","article-title":"Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I\/II study of the AGO Study Group (AGO-OVAR 2.13)","volume":"31","author":"Harter","year":"2013","journal-title":"Investigational New Drugs"},{"issue":"9","key":"10.1002\/14651858.CD007930.pub3-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"International Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/IGC.0b013e31827de69e","article-title":"Weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer: a preliminary result of 19 cases","volume":"23","author":"Ikeda","year":"2013","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2019.07.024","article-title":"Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours","volume":"120","author":"Jones","year":"2019","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2019.02.004","article-title":"Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Mullerian origin","volume":"153","author":"Krasner","year":"2019","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0255|cit255","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12957-022-02621-2","article-title":"Effect of bevacizumab combined with chemotherapy on SDF-1 and CXCR4 in epithelial ovarian cancer and its prognosis","volume":"20","year":"2022","journal-title":"World Journal of Surgical Oncology"},{"issue":"14","key":"10.1002\/14651858.CD007930.pub3-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1517\/14656560903120907","article-title":"Antiangiogenic drugs in ovarian cancer","volume":"10","author":"Markman","year":"2009","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"4","key":"10.1002\/14651858.CD007930.pub3-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s10147-021-02103-7","article-title":"Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer","volume":"27","author":"Nasu","year":"2022","journal-title":"International Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0258|cit258","unstructured":"Combination chemotherapy plus IM-862 in treating patients with resected stage III ovarian cancer or primary peritoneal cancer www.clinicaltrials.gov\/ct2\/show\/NCT00017303"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0259|cit259","unstructured":"A phase II study of tivozanib as maintenance therapy, post-chemotherapy, in patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer www.clinicaltrials.gov\/ct2\/show\/study\/NCT01972516"},{"issue":"18","key":"10.1002\/14651858.CD007930.pub3-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1016\/j.ejca.2013.08.002","article-title":"Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer","volume":"49","author":"Gonzalez-Martin","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD007930.pub3-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ejca.2013.12.001","article-title":"Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer)","volume":"50","author":"Gonzalez-Martin","year":"2014","journal-title":"European Journal of Cancer"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1200\/jco.2013.31.15_suppl.5544","article-title":"Efficacy and safety of front-line bevacizumab (BEV), weekly paclitaxel (wPAC), and q3w carboplatin (C) in elderly patients (pts) with ovarian cancer (OC): subgroup analysis of OCTAVIA","volume":"31","author":"Gonzalez-Martin","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1200\/jco.2012.30.15_suppl.5017","article-title":"Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): results from OCTAVIA","volume":"30","author":"Gonzalez-Martin","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"e15590","DOI":"10.1200\/jco.2011.29.15_suppl.e15590","article-title":"Bevacizumab alone or with chemotherapy in highly pretreated, relapsed, epithelial ovarian cancer patients","volume":"29","author":"Ojeda","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0265|cit265","unstructured":"Markman M Bevacizumab plus chemo extends progression-free survival: comment Oncology Report 2010 July-August 25"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0266|cit266","unstructured":"Osterweil N Bevacizumab plus chemo extends progression-free survival: comment Oncology Report 2010 July-August 25"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/1471-2407-11-453","article-title":"The PACOVAR-trial: A phase I\/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer","volume":"11","author":"Eichbaum","year":"2011","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ygyno.2020.01.005","article-title":"Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): a multi-centre, phase 1b and open-label, randomised phase 2 trial","volume":"156","author":"Morgan","year":"2020","journal-title":"Gynecologic Oncology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD007930.pub3-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"VIII342","DOI":"10.1093\/annonc\/mdy285.164","article-title":"A phase Ib and randomised phase II trial of pazopanib with or without fosbretabulin in advanced recurrent ovarian cancer","volume":"29","author":"Morgan","year":"2018","journal-title":"Annals of Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2021.39.15_suppl.5501","article-title":"Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): a multicenter open-label randomized 2-arm phase 3 ENGOT\/GCIG","volume":"39","author":"Pfisterer","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0271|cit271","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ejca.2022.07.022","article-title":"Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: main analysis of second progression-free survival in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"174","author":"Gonzalez-Martin","year":"2022","journal-title":"European Journal of Cancer"},{"issue":"16","key":"10.1002\/14651858.CD007930.pub3-BIB0272|cit272","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1200\/JCO.2022.40.16_suppl.5562","article-title":"Time without symptoms or toxicity (TWiST) in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib or placebo plus bevacizumab: analysis of PAOLA-1\/ENGOT-ov25 phase III trial","volume":"40","author":"Joly","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007930.pub3-BIB0273|cit273","doi-asserted-by":"publisher","first-page":"A201","DOI":"10.1136\/ijgc-2021-ESGO.346","article-title":"Safety and quality of life of first-line maintenance olaparib plus bevacizumab in older patients with advanced ovarian cancer in the paola-1 trial","volume":"31","author":"Montegut","year":"2021","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0090-8258(21)00695-8","article-title":"Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1\/ENGOT-ov25 trial","volume":"162","author":"Pujade-Lauraine","year":"2021","journal-title":"Gynecologic Oncology"},{"issue":"25","key":"10.1002\/14651858.CD007930.pub3-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ygyno.2013.01.006","article-title":"A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study","volume":"129","author":"Schilder","year":"2013","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0277|cit277","unstructured":"A phase II trial Of BAY 43-9006, a novel Raf kinase inhibitor plus paclitaxel\/carboplatin in women with recurrent platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer www.clinicaltrials.gov\/ct2\/show\/record\/NCT00096200"},{"issue":"4","key":"10.1002\/14651858.CD007930.pub3-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10637-014-0078-5","article-title":"Randomized phase II trial of sorafenib alone or in combination with carboplatin\/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer","volume":"32","author":"Schwandt","year":"2014","journal-title":"Investigational New Drugs"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4161\/cbt.9.3.11117","article-title":"Two is better than one: benefits of VEGF and PDGF inhibition in ovarian cancer","volume":"9","author":"Sennino","year":"2010","journal-title":"Cancer Biology and Therapy"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD007930.pub3-BIB0280|cit280","first-page":"S79 Abstract 18","article-title":"STAC: A phase II study of carboplatin\/paclitaxel\/bevacizumab followed by randomization to either bevacizumab alone or erlotinib and bevacizumab in the upfront management of patients with ovarian, fallopian tube or peritoneal cancer","volume":"120","author":"Campos","year":"2011","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0281|cit281","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2022.807377","article-title":"Comparison of neoadjuvant chemotherapy efficiency in advanced ovarian cancer patients treated with paclitaxel plus carboplatin and intraperitoneal bevacizumab vs. paclitaxel with carboplatin","volume":"9","author":"Tao","year":"2022","journal-title":"Frontiers in Medicine"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0282|cit282","unstructured":"Study of AVE0005 (VEGF Trap) in patients with chemoresistant advanced ovarian cancer www.clinicaltrials.gov\/ct2\/show\/NCT00327171"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/cncr.28406","article-title":"Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study","volume":"120","author":"Tew","year":"2014","journal-title":"Cancer"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1200\/jco.2007.25.18_suppl.5508","article-title":"VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study","volume":"25","author":"Tew","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0285|cit285","unstructured":"Bevacizumab with or without everolimus in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer www.clinicaltrials.gov\/ct2\/show\/NCT00886691"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ygyno.2018.08.027","article-title":"Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: an NRG oncology\/gynecologic oncology group study","volume":"151","author":"Tew","year":"2018","journal-title":"Gynecologic Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1200\/jco.2012.30.15_suppl.5014","article-title":"Phase I trial of metronomic oral topotecan in combination with pazopanib utilizing a daily dosing schedule to treat recurrent or persistent gynecologic tumors","volume":"30","author":"Tillmanns","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2012.08.039","article-title":"Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma","volume":"128","author":"Tillmanns","year":"2013","journal-title":"Gynecologic Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007930.pub3-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"S624","DOI":"10.1016\/j.annonc.2020.08.968","article-title":"Regorafenib (R) or tamoxifen (T) for platinum-sensitive recurrent ovarian cancer (PSROC) with rising CA125 and no evidence of clinical or radiological disease progression: a GINECO randomized phase II trial","volume":"31","author":"Tredan","year":"2020","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2021.09.024","article-title":"Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: a GINECO randomized phase II trial (REGOVAR)","volume":"164","author":"Tredan","year":"2022","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"e372021","DOI":"10.3802\/jgo.2021.32.e37","article-title":"Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group","volume":"32","author":"Trillsch","year":"2021","journal-title":"Journal of Gynecologic Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/jco.2011.29.15_suppl.5008","article-title":"Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT)","volume":"29","author":"Buckanovich","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007930.pub3-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"TPS188","DOI":"10.1200\/jco.2010.28.15_suppl.tps188","article-title":"An adaptive randomized discontinuation trial of XL184 (BMS-907351) in patients (pts) with advanced solid tumors","volume":"28","author":"Gordon","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0294|cit294","unstructured":"Study of cabozantinib (XL184) in adults with advanced malignancies www.clinicaltrials.gov\/ct2\/show\/NCT00940225"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejca.2017.06.018","article-title":"A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma","volume":"83","author":"Vergote","year":"2017","journal-title":"European Journal of Cancer"},{"issue":"12","key":"10.1002\/14651858.CD007930.pub3-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1093\/annonc\/mds172","article-title":"Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer","volume":"23","author":"Verschraegen","year":"2012","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2013.04.049","article-title":"A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy","volume":"130","author":"Wenham","year":"2013","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0298|cit298","first-page":"80","article-title":"Efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients","volume":"25","author":"Zhang","year":"2020","journal-title":"Journal of B.U.ON."},{"key":"10.1002\/14651858.CD007930.pub3-BIB0299|cit299","unstructured":"Bevacizumab and carboplatin for patients with ovarian cancer www.clinicaltrials.gov\/ct2\/show\/study\/NCT00744718"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0300|cit300","unstructured":"Avelumab and talazoparib in untreated advanced ovarian cancer (JAVELIN OVARIAN PARP 100) www.clinicaltrials.gov\/ct2\/show\/study\/NCT03642132"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/ijgc-2020-002073","article-title":"ICON 9 - an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy","volume":"31","author":"Elyashiv","year":"2021","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0302|cit302","unstructured":"Study evaluating the efficacy of maintenance olaparib and cediranib or olaparib alone in ovarian cancer patients (ICON9) www.clinicaltrials.gov\/ct2\/show\/NCT03278717"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0303|cit303","unstructured":"Efficacy and safety study of M200 (volociximab in combination with liposomal doxorubicin) www.clinicaltrials.gov\/ct2\/show\/NCT00635193"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0304|cit304","unstructured":"Phase 1\/2a\/3 Evaluation of adding AL3818 to standard platinum-based chemotherapy in subjects with recurrent or metastatic endometrial, ovarian, fallopian, primary peritoneal or cervical carcinoma (AL3818-US-002) (AL3818) www.clinicaltrials.gov\/ct2\/show\/study\/NCT02584478"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0305|cit305","unstructured":"Pegylated liposomal doxorubicin hydrochloride with atezolizumab and\/or bevacizumab in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer www.clinicaltrials.gov\/ct2\/show\/study\/NCT02839707"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0306|cit306","unstructured":"Intraperitoneal chemotherapy alone or in combination with bevacizumab for ovarian cancer with peritoneal adhesion www.clinicaltrials.gov\/ct2\/show\/study\/NCT03095001"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0307|cit307","unstructured":"Efficacy and safety of apatinib as third line therapy in patients with advanced ovarian cancer www.clinicaltrials.gov\/ct2\/show\/NCT03262545"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0308|cit308","unstructured":"Carboplatin-paclitaxel-bevacizumab vs carbo-pacli-beva-rucaparib vs carbo-pacli-ruca, selected according to hrd status, in patients with advanced ovarian, primary peritoneal and fallopian tube cancer, preceded by a phase i dose escalation study on ruca-beva combination (MITO25) www.clinicaltrials.gov\/ct2\/show\/NCT03462212"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD007930.pub3-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"S401","DOI":"10.1016\/j.annonc.2022.04.063","article-title":"45TiP A randomized, molecular driven phase II trial of carboplatin-paclitaxel-bev vs carboplatin-paclitaxel-bev-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced ovarian cancer","volume":"33","author":"Scambia","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0310|cit310","unstructured":"A study of the efficacy and safety of bevacizumab in chinese women with newly diagnosed, previously untreated stage III or stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer www.clinicaltrials.gov\/ct2\/show\/NCT03635489"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0311|cit311","unstructured":"A phase III study of BD0801 combined with chemotherapy in recurrent, platinum-resistant epithelial ovarian cancer www.clinicaltrials.gov\/ct2\/show\/NCT04908787"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0312|cit312","unstructured":"APL-2 and pembrolizumab versus APL-2, pembrolizumab and bevacizumab versus bevacizumab alone for the treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer and malignant effusion www.clinicaltrials.gov\/ct2\/show\/study\/NCT04919629"},{"issue":"16","key":"10.1002\/14651858.CD007930.pub3-BIB0313|cit313","doi-asserted-by":"publisher","first-page":"TPS5612","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5612","article-title":"AGO-OVAR 28\/ENGOT-ov57: niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer-A multicenter, randomized, phase III trial","volume":"40","author":"Heitz","year":"2022","journal-title":"Journal of Clinical Oncology\u00a0"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0314|cit314","unstructured":"Niraparib vs niraparib plus bevacizumab in patients with platinum\/taxane-based chemotherapy in advanced ovarian cancer www.clinicaltrials.gov\/ct2\/show\/study\/NCT05009082"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0315|cit315","unstructured":"A study of navicixizumab in patients with platinum resistant ovarian cancer www.clinicaltrials.gov\/ct2\/show\/NCT05043402"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0316|cit316","unstructured":"A study of bevacizumab combined with fluzoparib\/chemotherapy or fluzoparib in the treatment of ovarian cancer www.clinicaltrials.gov\/ct2\/show\/NCT05170594"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0317|cit317","unstructured":"Niraparib with bevacizumab after complete cytoreduction in patients with ovarian cancer (NIRVANA-1) www.clinicaltrials.gov\/ct2\/show\/study\/NCT05183984"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0318|cit318","unstructured":"Bevacizumab and\/or niraparib in patients with recurrent endometrial and\/or ovarian cancer with ARID1A mutation (ARID1A) www.clinicaltrials.gov\/ct2\/show\/study\/NCT05523440"},{"issue":"10","key":"10.1002\/14651858.CD007930.pub3-BIB0319|cit319","first-page":"1011","article-title":"Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with \"standard of care\" therapeutic agents for the treatment of breast cancer","volume":"2","author":"Abrams","year":"2003","journal-title":"Molecular Cancer Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.2696","article-title":"Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary","volume":"221","author":"Ahmed","year":"2010","journal-title":"Journal of Pathology"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ygyno.2021.05.018","article-title":"Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: a review","volume":"162","author":"Alvarez Secord","year":"2021","journal-title":"Gynecologic Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007930.pub3-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ijgo.12614","article-title":"Cancer of the ovary, fallopian tube, and peritoneum","volume":"143","author":"Berek","year":"2018","journal-title":"International Journal of Gynecology & Obstetrics"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0323|cit323","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejogrb.2017.04.016","article-title":"British Gynaecological Cancer Society (BGCS) epithelial ovarian \/ fallopian tube \/ primary peritoneal cancer guidelines: recommendations for practice","volume":"213","author":"Fotopoulou","year":"2017","journal-title":"European Journal of Obstetrics, Gynecology and Reproductive Biology"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1535-7163.MCT-09-0472","article-title":"The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases","volume":"9","author":"Bhide","year":"2010","journal-title":"Molecular Cancer Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD007930.pub3-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1158\/1535-7163.MCT-10-0976","article-title":"Assessing the activity of cediranib, a VEGFR-2\/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family","volume":"10","author":"Brave","year":"2011","journal-title":"Molecular Cancer Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD007930.pub3-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"100229","DOI":"10.1016\/j.esmoop.2021.100229","article-title":"Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores","volume":"6","author":"Broekman","year":"2021","journal-title":"ESMO Open"},{"issue":"33","key":"10.1002\/14651858.CD007930.pub3-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer","volume":"25","author":"Burger","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007930.pub3-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1021\/jm7013309","article-title":"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4] triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)","volume":"51","author":"Cai","year":"2008","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0329|cit329","unstructured":"Cancer Research UK Ovarian cancer five-year net survival by stage, with incidence by stage (all data: adults diagnosed 2013-2017, followed up to 2018) www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/ovarian-cancer\/survival#heading-Three"},{"issue":"33","key":"10.1002\/14651858.CD007930.pub3-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD007930.pub3-BIB0331|cit331","first-page":"7284","article-title":"ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases","volume":"62","author":"Carlomagno","year":"2002","journal-title":"Cancer Research"},{"issue":"11","key":"10.1002\/14651858.CD007930.pub3-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"e203754","DOI":"10.1001\/jamasurg.2020.3754","article-title":"Patient-centered time-at-home outcomes in older adults after surgical cancer treatment","volume":"155","author":"Chesney","year":"2020","journal-title":"JAMA Surgery"},{"issue":"13","key":"10.1002\/14651858.CD007930.pub3-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2217\/fon-2021-0565","article-title":"Molecular methods for increasing the effectiveness of ovarian cancer treatment: a systematic review","volume":"18","author":"Chilimoniuk","year":"2022","journal-title":"Future Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10555-014-9538-9","article-title":"Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches","volume":"34","author":"Choi","year":"2015","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s11912-013-0368-7","article-title":"Aflibercept - a decoy VEGF receptor","volume":"16","author":"Ciombor","year":"2014","journal-title":"Current Oncology Reports"},{"issue":"7","key":"10.1002\/14651858.CD007930.pub3-BIB0336|cit336","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005343.pub6","article-title":"Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer","author":"Coleridge","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD007930.pub3-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0338|cit338","unstructured":"Covidence Veritas Health Innovation"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0339|cit339","unstructured":"Core outcomes in women's and newborn health www.crown-initiative.org."},{"key":"10.1002\/14651858.CD007930.pub3-BIB0340|cit340","unstructured":"Cancer Therapy Evaluation Program (CTEP) Common terminology criteria for adverse events (CTCAE), version 3.0, DCTD, NCI, NIH, DHHS; August 2006 ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0341|cit341","volume-title":"Systematic Reviews in Health Care: Meta-Analysis in Context","author":"Deeks","year":"2001"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ygyno.2019.01.010","article-title":"Apatinib exerts anti-tumour effects on ovarian cancer cells","volume":"153","author":"Ding","year":"2019","journal-title":"Gynecologic Oncology"},{"issue":"7","key":"10.1002\/14651858.CD007930.pub3-BIB0343|cit343","doi-asserted-by":"publisher","first-page":"dju128","DOI":"10.1093\/jnci\/dju128","article-title":"Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials","volume":"106","author":"Donovan","year":"2014","journal-title":"Journal of the National Cancer Institute"},{"issue":"18","key":"10.1002\/14651858.CD007930.pub3-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/S0959-8049(02)00495-1","article-title":"Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate","volume":"38","author":"Engel","year":"2002","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.03-0271fje","article-title":"Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms","volume":"18","author":"Erber","year":"2004","journal-title":"FASEB Journal"},{"issue":"5","key":"10.1002\/14651858.CD007930.pub3-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nature Reviews Drug Discovery"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0092-8674(94)90187-2","article-title":"The implications of angiogenesis for the biology and therapy of cancer metastasis","volume":"79","author":"Fidler","year":"1994","journal-title":"Cell"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","article-title":"What is the evidence that tumors are angiogenesis dependent?","volume":"82","author":"Folkman","year":"1990","journal-title":"Journal of National Cancer Institute"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0349|cit349","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1038\/s41598-022-07731-1","article-title":"A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer","volume":"12","author":"Helali","year":"2022","journal-title":"Scientific Reports"},{"issue":"7414","key":"10.1002\/14651858.CD007930.pub3-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0352|cit352","unstructured":"Higgins JP Altman DG Sterne JA on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"12","key":"10.1002\/14651858.CD007930.pub3-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"103336","DOI":"10.1016\/j.critrevonc.2021.103336","article-title":"Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: a systematic review","volume":"162","author":"Hirte","year":"2021","journal-title":"Critical Reviews in Oncology-Hematology"},{"issue":"7","key":"10.1002\/14651858.CD007930.pub3-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Human Pathology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"x16","DOI":"10.1093\/annonc\/mdt463","article-title":"Origin and molecular pathogenesis of ovarian high-grade serous carcinoma","volume":"24 Suppl 10","author":"Kurman","year":"2013","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nature Communications"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24 Suppl 6","author":"Ledermann","year":"2013","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0359|cit359","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ygyno.2021.01.028","article-title":"The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis","volume":"161","author":"Liu","year":"2021","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1749-6632.1999.tb08726.x","article-title":"COX-2 inhibitors. A new class of antiangiogenic agents","volume":"889","author":"Masferrer","year":"1999","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"5","key":"10.1002\/14651858.CD007930.pub3-BIB0362|cit362","first-page":"1306","article-title":"Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors","volume":"60","author":"Masferrer","year":"2000","journal-title":"Cancer Research"},{"issue":"18","key":"10.1002\/14651858.CD007930.pub3-BIB0363|cit363","first-page":"5381","article-title":"Significance of blood vessel leakiness in cancer","volume":"62","author":"McDonald","year":"2002","journal-title":"Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0364|cit364","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"10.1002\/14651858.CD007930.pub3-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s11136-016-1339-x","article-title":"The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols","volume":"25","author":"Mercieca-Bebber","year":"2016","journal-title":"Quality of Life Research"},{"issue":"10","key":"10.1002\/14651858.CD007930.pub3-BIB0366|cit366","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007927.pub4","article-title":"Epidermal growth factor receptor blockers for the treatment of ovarian cancer","author":"Morrison","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2006.08.032","article-title":"Results from an in vitro and a clinical\/pharmacological phase I study with the combination irinotecan and sorafenib","volume":"43","author":"Mross","year":"2007","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0368|cit368","unstructured":"National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer NCCN Guidelines. Available from www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1453 2022 Version 1 January 18"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0369|cit369","unstructured":"National Cancer Institute: Division of Cancer Treatment and Diagnosis NCI Formulary: Cediranib (AZD2171, RECENTIN) Available at: nciformulary.cancer.gov\/available_agents\/Cediranib.htm"},{"issue":"4","key":"10.1002\/14651858.CD007930.pub3-BIB0370|cit370","first-page":"487","article-title":"AMG-386, a selective angiopoietin-1\/-2-neutralizing peptibody for the potential treatment of cancer","volume":"12","author":"Neal","year":"2010","journal-title":"Current Opinion in Molecular Therapeutics"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0371|cit371","article-title":"Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer","author":"Newhouse","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0372|cit372","unstructured":"NICE (National Institute for Health and Care Excellence) British National Formulary (BNF) Available from bnf.nice.org.uk\/ 2022"},{"issue":"6D","key":"10.1002\/14651858.CD007930.pub3-BIB0373|cit373","first-page":"5109","article-title":"Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer","volume":"20","author":"Oehler","year":"2000","journal-title":"Anticancer Research"},{"issue":"5","key":"10.1002\/14651858.CD007930.pub3-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ccr.2004.09.030","article-title":"Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2","volume":"6","author":"Oliner","year":"2004","journal-title":"Cancer Cell"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD007930.pub3-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"x111","DOI":"10.1093\/annonc\/mds300","article-title":"New insights into ovarian cancer pathology","volume":"23","author":"Prat","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","article-title":"Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics","volume":"80","author":"Prat","year":"2018","journal-title":"Human Pathology"},{"issue":"9","key":"10.1002\/14651858.CD007930.pub3-BIB0377|cit377","doi-asserted-by":"crossref","first-page":"9902","DOI":"10.21037\/apm-21-1662","article-title":"Evaluation of safety and efficacy of apatinib combination with chemotherapy for ovarian cancer treatment: a systematic review and meta-analysis","volume":"10","author":"Qi","year":"2021","journal-title":"Annals of Palliative Medicine"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0378|cit378","volume-title":"Cancer Trends in England and Wales","author":"Quinn","year":"2001"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0379|cit379","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1002\/sim.3623","article-title":"The estimation of average hazard ratios by weighted Cox regression","volume":"28","author":"Schemper","year":"2009","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0380|cit380","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Akl E on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group Chapter 11: Completing \u2018Summary of findings\u2019 tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0381|cit381","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P on behalf of the Cochrane Applicability and Recommendations Methods Group Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017) Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"259","DOI":"10.11124\/JBISRIR-D-19-00059","article-title":"Interactive summary of findings tables: the way to present and understand results of systematic reviews","volume":"17","author":"Sch\u00fcnemann","year":"2019","journal-title":"JBI Database Systematic Reviews and Implementation Reports"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2009.27.8911","article-title":"Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group","volume":"29","author":"Sehouli","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007930.pub3-BIB0384|cit384","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00432-016-2307-0","article-title":"A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO)","volume":"143","author":"Sehouli","year":"2017","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ajpath.2020.09.006","article-title":"The origin of ovarian cancer species and precancerous landscape","volume":"191","author":"Shih I","year":"2021","journal-title":"American Journal of Pathology"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0386|cit386","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1158\/1078-0432.CCR-05-1571","article-title":"Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer","volume":"12","author":"Siu","year":"2006","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11912-007-0007-2","article-title":"Pazopanib: a novel multitargeted tyrosine kinase inhibitor","volume":"9","author":"Sonpavde","year":"2007","journal-title":"Current Oncology Reports"},{"issue":"1","key":"10.1002\/14651858.CD007930.pub3-BIB0389|cit389","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001418","article-title":"Chemotherapy for advanced ovarian cancer","author":"Stewart","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD007930.pub3-BIB0390|cit390","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007929.pub4","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer","author":"Tattersall","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD007930.pub3-BIB0391|cit391","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","article-title":"YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo","volume":"102","author":"Tian","year":"2011","journal-title":"Cancer Science"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0392|cit392","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"16","key":"10.1002\/14651858.CD007930.pub3-BIB0393|cit393","first-page":"4645","article-title":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration","volume":"62","author":"Wedge","year":"2002","journal-title":"Cancer Research"},{"issue":"10","key":"10.1002\/14651858.CD007930.pub3-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1158\/0008-5472.CAN-04-4409","article-title":"AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer","volume":"65","author":"Wedge","year":"2005","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0395|cit395","volume-title":"WHO Classification of Tumours 5th Edition: Female Genital Tumours","year":"2020"},{"key":"10.1002\/14651858.CD007930.pub3-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1186\/s12885-021-08859-5","article-title":"Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment","volume":"21","author":"Xue","year":"2021","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1002\/14651858.CD007930.pub3-BIB0397|cit397","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Molecular Cancer Therapeutics"},{"issue":"15","key":"10.1002\/14651858.CD007930.pub3-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1073\/pnas.0813061106","article-title":"VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis","volume":"106","author":"Zhang","year":"2009","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"9","key":"10.1002\/14651858.CD007930.pub3-BIB0399|cit399","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007930.pub2","article-title":"Angiogenesis inhibitors for the treatment of ovarian cancer","author":"Gaitskell","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T20:57:33Z","timestamp":1760389053000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007930.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":399,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007930.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]}}}